PTC Therapeutics dropped 7% on October 30 to $59.97, a sharper single-day move than most of its rare-disease peers absorbed this week, yet the short position that was 11.4% of free float a week ago has continued to shrink. Short interest now stands at 10.1% of free float, down 11.7% on the week and 18.2% over the past month. The pace of covering actually accelerated around the…
PTCT short interest plunges 42% in one week to 11.9% of float, driven by covering amid analyst upgrades and stronger-than-expected Q2 results.
Key data as of 12 Nov 2026
PTC Therapeutics heads into the week with a stock that has rallied 15% over the past month but shed 5.2% on Thursday, while the CTO cashed out more than $2 million at the highs — a combination that puts the bull…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for PTCT — free to start on ORTEX.
Sign up for free →Open PTCT on ORTEX